Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 CC-90010 dose-finding study in advanced solid tumors and relapsed/refractory non-Hodgkin lymphomas
jRCT2080225176Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of trotabresib in Nonhematologic neoplasms, non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and 3 more (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety, Tolerability and 1 more. Started Apr 2020; status: completed.
02
Drugs
trotabresib
03
Conditions
Nonhematologic neoplasmsnon-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2080225176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225176.